Distribuzione geografica
Continente #
EU - Europa 36.413
NA - Nord America 3.915
AS - Asia 269
SA - Sud America 5
AF - Africa 2
OC - Oceania 1
Totale 40.605
Nazione #
IT - Italia 35.927
US - Stati Uniti d'America 3.905
SE - Svezia 279
CN - Cina 132
FI - Finlandia 79
SG - Singapore 68
GB - Regno Unito 62
DE - Germania 39
VN - Vietnam 32
HK - Hong Kong 24
FR - Francia 7
AT - Austria 6
CA - Canada 6
IN - India 6
BR - Brasile 5
GR - Grecia 4
MX - Messico 4
NL - Olanda 3
IS - Islanda 2
JP - Giappone 2
UA - Ucraina 2
AU - Australia 1
IE - Irlanda 1
IR - Iran 1
KR - Corea 1
LU - Lussemburgo 1
MY - Malesia 1
NG - Nigeria 1
PH - Filippine 1
RS - Serbia 1
UG - Uganda 1
YE - Yemen 1
Totale 40.605
Città #
Cagliari 35.821
Fairfield 883
Woodbridge 403
Ashburn 378
Seattle 376
Houston 321
Cambridge 318
Wilmington 294
Nyköping 253
Ann Arbor 108
Helsinki 79
Boston 78
Jacksonville 78
Boardman 57
Chandler 46
New York 46
San Diego 42
Dearborn 37
Beijing 33
Dong Ket 32
Rome 32
Shanghai 32
Redwood City 31
London 18
Mountain View 17
Nanjing 15
Norwalk 10
Atlanta 8
Kilburn 8
Kunming 8
Milan 8
Redmond 8
Oxford 7
Vienna 6
Chengdu 5
Chiswick 5
Turin 5
Borås 4
Chicago 4
Jinan 4
Mexico City 4
Nanchang 4
Pune 4
Stockholm 4
Stockport 4
Toronto 4
Zhengzhou 4
Augusta 3
Collegeville 3
Florence 3
Hounslow 3
Islington 3
Milazzo 3
Patras 3
Rockville 3
Sadali 3
San Mateo 3
Singapore 3
Amsterdam 2
Anqing 2
Barletta 2
Cedar Knolls 2
Central 2
Cormano 2
Denver 2
Fiesole 2
Greensboro 2
Guangzhou 2
Hebei 2
Hefei 2
Hong Kong 2
Isernia 2
Krefeld 2
Montecassiano 2
New Bedfont 2
Paris 2
Phoenix 2
Reading 2
Rende 2
Reykjavik 2
Sassari 2
Sestu 2
Stony Brook 2
Tacoma 2
Venice 2
Abuja 1
Acton 1
Aubers 1
Belgrade 1
Berkeley 1
Bracke 1
Caloocan City 1
Carimate 1
Central District 1
Conversano 1
Council Bluffs 1
Dublin 1
Encino 1
Esslingen am Neckar 1
Fuzhou 1
Totale 40.048
Nome #
Comparative Efficacy of Vedolizumab and Adalimumab in Ulcerative Colitis Patients Previously Treated With Infliximab 1.714
Nonalcoholic fatty liver disease in patients with inflammatory bowel disease: Beyond the natural history 1.578
Outcomes of COVID-19 in 79 patients with IBD in Italy: An IG-IBD study 972
Multidimensional Impact of Mediterranean Diet on IBD Patients 954
Outcome in ulcerative colitis after switch from adalimumab/golimumab to infliximab: A multicenter retrospective study 944
RORGT-expressing tregs drive the growth of colitis-associated colorectal cancer by controlling IL6 in dendritic cells 880
Use of biosimilars in inflammatory bowel disease: a position update of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD) 863
Response Assessed by Ultrasonography as Target of Biological Treatment for Crohn's Disease 861
Immunological Variables Associated With Clinical and Endoscopic Response to Vedolizumab in Patients With Inflammatory Bowel Diseases 824
The Resolution of Intestinal Inflammation: The Peace-Keeper's Perspective 771
Reciprocal regulation between Smad7 and Sirt1 in the gut 746
Heligmosomoides polygyrus bakeri infection decreases Smad7 expression in intestinal CD4+ T cells, which allows TGF-b to induce IL-10–producing regulatory T cells that block colitis 743
Tbet Expression in Regulatory T Cells Is Required to Initiate Th1-Mediated Colitis 733
CCL20 Is Negatively Regulated by TGF-β1 in Intestinal Epithelial Cells and Reduced in Crohn's Disease Patients With a Successful Response to Mongersen, a Smad7 Antisense Oligonucleotide 711
Are we choosing wisely for inflammatory bowel disease care? The IG-IBD choosing wisely campaign 701
Update on the Therapeutic Efficacy of Tregs in IBD: Thumbs up or Thumbs down? 697
The Role of Gut Microbiota Biomodulators on Mucosal Immunity and Intestinal Inflammation 689
Mongersen, an oral SMAD7 antisense oligonucleotide, and Crohn's disease 675
Smad7 knockdown activates protein kinase RNA-associated eIF2α pathway leading to colon cancer cell death 648
A functional role for Smad7 in sustaining colon cancer cell growth and survival 634
Th17-type cytokines, IL-6 and TNF-α synergistically activate STAT3 and NF-kB to promote colorectal cancer cell growth 629
null 617
Activation of TGF-β-induced non-Smad signaling pathways during Th17 differentiation 601
Dual Targeted Therapy: a possible option for the management of refractory Inflammatory Bowel Disease 582
Tumor infiltrating regulatory t cells in sporadic and colitis-associated colorectal cancer: The red little riding hood and the wolf 582
Quercetin and its derivates as antiviral potentials: A comprehensive review 578
A phase 1 open-label trial shows that smad7 antisense oligonucleotide (GED0301) does not increase the risk of small bowel strictures in Crohn's disease 572
Inhibition of colitis by IL-25 associates with induction of alternatively activated macrophages 508
Smad7 induces plasticity in tumor-infiltrating Th17 cells and enables TNF-alpha-mediated killing of colorectal cancer cells 497
2-methoxy-5-amino-N-hydroxybenzamide sensitizes colon cancer cells to TRAIL-induced apoptosis by regulating death receptor 5 and survivin expression 493
Smad7 expression in T cells prevents colitis-associated cancer 488
Smad7 in intestinal CD4+ T cells determines autoimmunity in a spontaneous model of multiple sclerosis 464
The impact of translational research on gastroenterology 461
Reprogramming the immune system in IBD 431
Phase I clinical trial of Smad7 knockdown using antisense oligonucleotide in patients with active Crohn's disease 417
Interleukin-21 sustains inflammatory signals that contribute to sporadic colon tumorigenesis 413
Expert consensus paper on the use of Vedolizumab for the management of patients with moderate-to-severe Inflammatory Bowel Disease 402
A Pharmacological Batch of Mongersen that Downregulates Smad7 is Effective as Induction Therapy in Active Crohn’s Disease: A Phase II, Open-Label Study 380
Smad7 Controls Resistance of Colitogenic T Cells to Regulatory T Cell-Mediated Suppression 337
Inhibition of colon carcinogenesis by 2-methoxy-5-amino-N-hydroxybenzamide, a novel derivative of mesalamine 335
Regulation of homeostasis and inflammation in the intestine 325
Common immunologic mechanisms in inflammatory bowel disease and spondylarthropathies 313
Interferon-gamma-expressing cells are a major source of interleukin-21 in inflammatory bowel diseases 311
Involvement of interleukin-21 in the regulation of colitis-associated colon cancer 308
The lymphatic system controls intestinal inflammation and inflammation-associated Colon Cancer through the chemokine decoy receptor D6 299
Immune system and gut microbiota senescence in elderly IBD patients 296
Intestinal inflammation and colorectal cancer: a double-edged sword? 294
From inflammation to colitis-associated colorectal cancer in inflammatory bowel disease: Pathogenesis and impact of current therapies 278
Interleukin-25 inhibits interleukin-12 production and Th1 cell-driven inflammation in the gut 273
Inhibition of monocyte-derived inflammatory cytokines by IL-25 occurs via a p38 Map kinase-dependent induction of SOCS-3 273
Unique role of junctional adhesion molecule-A in maintaining mucosal homeostasis in inflammatory bowel disease 269
Cyclooxygenase-2-dependent and -independent inhibition of proliferation of colon cancer cells by 5-aminosalicylic acid 265
An Objective Comparison of Vedolizumab and Ustekinumab Effectiveness in Crohn's Disease Patients' Failure to TNF-Alpha Inhibitors 259
Angiogenesis, immune system and growth factors: new targets in colorectal cancer therapy 257
In vitro generation of CD4+ CD25+ regulatory cells from murine naive T cells 247
High resolution colonoscopy in live mice 242
TGF-beta suppresses tumor progression in colon cancer by inhibition of IL-6 trans-signaling 239
Mesalazine negatively regulates CDC25A protein expression and promotes accumulation of colon cancer cells in S phase 238
Lactobacillus paracasei subsp. paracasei B21060 suppresses human T-cell proliferation 238
Drug insight: novel small molecules and drugs for immunosuppression 237
TGF-beta as a T cell regulator in colitis and colon cancer 236
Spatiotemporal patterns of expression of neurotrophins and neurotrophin receptors in mice suggest functional roles in testicular and epididymal morphogenesis 230
Regulation of gut inflammation and th17 cell response by interleukin-21 230
In vivo imaging of colitis and colon cancer development in mice using high resolution chromoendoscopy 230
Cutting edge: trans-signaling via the soluble IL-6R abrogates the induction of FoxP3 in naive CD4+CD25 T cells 228
Cytokines: from gut inflammation to colorectal cancer 227
IL-27 controls the development of inducible regulatory T cells and Th17 cells via differential effects on STAT1 224
IL-21 comes of age as a regulator of effector T cells in the gut 221
Cutting edge: IL-23 cross-regulates IL-12 production in T cell-dependent experimental colitis 219
Seroprevalence of SARS-CoV2 in IBD patients treated with biologic therapy 218
Defining Comprehensive Disease Control for use as a Treatment Target for Ulcerative Colitis in Clinical Practice: International Delphi Consensus Recommendations 216
Cutting edge: TGF-beta induces a regulatory phenotype in CD4+CD25- T cells through Foxp3 induction and down-regulation of Smad7 212
Fecal alpha 1-antitrypsin clearance as a marker of clinical relapse in patients with Crohn's disease of the distal ileum 210
Activities related to inflammatory bowel disease management during and after the coronavirus disease 2019 lockdown in Italy: How to maintain standards of care 209
Control of matrix metalloproteinase production in human intestinal fibroblasts by interleukin 21 208
Selective cyclooxygenase-2 inhibitors and relapse of inflammatory bowel disease 208
Use of biologics and small molecule drugs for the management of moderate to severe ulcerative colitis: IG-IBD clinical guidelines based on the GRADE methodology 208
New players in the cytokine orchestra of inflammatory bowel disease 206
IL-23-mediated regulation of IL-17 production in Helicobacter pylori-infected gastric mucosa 203
IL-21 counteracts the regulatory T cell-mediated suppression of human CD4+ T lymphocytes 203
IL-6 signaling promotes tumor growth in colorectal cancer 201
Alternative Splice Forms of CYLD Mediate Ubiquitination of SMAD7 to Prevent TGFB Signaling and Promote Colitis 200
EBV-induced gene 3 transcription is induced by TLR signaling in primary dendritic cells via NF-kappa B activation 189
TNF-alpha and IFN-gamma regulate the expression of the NOD2 (CARD15) gene in human intestinal epithelial cells 187
Telemedicine and remote screening for COVID-19 in inflammatory bowel disease patients: results from the SoCOVID-19 survey 183
Reduced humoral response to two doses of COVID-19 vaccine in patients with inflammatory bowel disease: Data from ESCAPE-IBD, an IG-IBD study 181
A failure of transforming growth factor-beta1 negative regulation maintains sustained NF-kappaB activation in gut inflammation 180
A functional role for interleukin-21 in promoting the synthesis of the T-cell chemoattractant, MIP-3alpha, by gut epithelial cells 179
Clinical and epidemiological features of ulcerative colitis patients in Sardinia, Italy: Results from a multicenter study 178
Role of interleukin-21 in inflammation and allergy 178
Review article: maintenance treatment of Crohn's disease 176
Transforming growth factor beta induced FoxP3+ regulatory T cells suppress Th1 mediated experimental colitis 173
IL-21 is highly produced in Helicobacter pylori-infected gastric mucosa and promotes gelatinases synthesis 165
IL-21 regulates experimental colitis by modulating the balance between T(reg) and Th17 cells 162
Advanced imaging and Crohn's disease: An overview of clinical application and the added value of artificial intelligence 157
Diagnostic delay in adult coeliac disease: An Italian multicentre study 156
GPR120/FFAR4: A Potential New Therapeutic Target for Inflammatory Bowel Disease 153
Comparison of two strategies for the management of postoperative recurrence in Crohn's disease patients with one clinical risk factor: A multicentre IG-IBD study 152
IL10 Secretion Endows Intestinal Human iNKT Cells with Regulatory Functions Towards Pathogenic T Lymphocytes 151
Timing of proper introduction, optimization and maintenance of anti-TNF therapy in IBD: Results from a Delphi consensus 147
Totale 40.380
Categoria #
all - tutte 64.507
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 64.507

Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/201923 0 0 0 0 0 0 0 0 0 0 10 13
2019/20203.381 15 17 3 7 400 1.044 824 292 301 197 114 167
2020/202111.977 314 443 429 3.707 2.960 1.125 762 650 179 386 369 653
2021/20225.699 362 462 288 255 479 473 250 494 442 691 871 632
2022/20239.989 797 1.203 1.202 524 662 1.418 640 939 577 649 811 567
2023/20249.848 522 435 373 894 1.421 2.156 2.253 819 617 358 0 0
Totale 40.917